Format

Send to

Choose Destination
J Neurochem. 2017 Sep;142(5):624-648. doi: 10.1111/jnc.14098. Epub 2017 Jul 5.

Endocannabinoid system in neurodegenerative disorders.

Author information

1
Division of Analytical Psychopharmacology, Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, USA.
2
New York State Psychiatric Institute, New York City, New York, USA.
3
Department of Psychiatry, College of Physicians & Surgeons, Columbia University, New York City, New York, USA.
4
Department of Psychiatry, New York University Langone Medical Center, New York City, New York, USA.

Abstract

Most neurodegenerative disorders (NDDs) are characterized by cognitive impairment and other neurological defects. The definite cause of and pathways underlying the progression of these NDDs are not well-defined. Several mechanisms have been proposed to contribute to the development of NDDs. These mechanisms may proceed concurrently or successively, and they differ among cell types at different developmental stages in distinct brain regions. The endocannabinoid system, which involves cannabinoid receptors type 1 (CB1R) and type 2 (CB2R), endogenous cannabinoids and the enzymes that catabolize these compounds, has been shown to contribute to the development of NDDs in several animal models and human studies. In this review, we discuss the functions of the endocannabinoid system in NDDs and converse the therapeutic efficacy of targeting the endocannabinoid system to rescue NDDs.

KEYWORDS:

Alzheimer's disease; CB1 receptors; Huntington's disease; Loss of neurons; Parkinson's disease; motor and memory behavior

PMID:
28608560
PMCID:
PMC5669051
DOI:
10.1111/jnc.14098
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center